Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease

PLoS One. 2016 Apr 1;11(4):e0152549. doi: 10.1371/journal.pone.0152549. eCollection 2016.

Abstract

Background: Accumulating evidence has shown that methionine- and choline-deficient high fat (MCD+HF) diet induces the development of nonalcoholic fatty liver disease (NAFLD), in which elevated reactive oxygen species play a crucial role. We have reported that peroxiredoxin 4 (PRDX4), a unique secretory member of the PRDX antioxidant family, protects against NAFLD progression. However, the detailed mechanism and potential effects on the intestinal function still remain unclear.

Methods & results: Two weeks after feeding mice a MCD+HF diet, the livers of human PRDX4 transgenic (Tg) mice exhibited significant suppression in the development of NAFLD compared with wild-type (WT) mice. The serum thiobarbituric acid reactive substances levels were significantly lower in Tg mice. In contrast, the Tg small intestine with PRDX4 overexpression showed more suppressed shortening of total length and villi height, and more accumulation of lipid in the jejunum, along with lower levels of dihydroethidium binding. The enterocytes exhibited fewer apoptotic but more proliferating cells, and inflammation was reduced in the mucosa. Furthermore, the small intestine of Tg mice had significantly higher expression of cholesterol absorption-regulatory factors, including liver X receptor-α, but lower expression of microsomal triglyceride-transfer protein.

Conclusion: Our present data provide the first evidence of the beneficial effects of PRDX4 on intestinal function in the reduction of the severity of NAFLD, by ameliorating oxidative stress-induced local and systemic injury. We can suggest that both liver and intestine are spared, to some degree, by the antioxidant properties of PRDX4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Disease Progression
  • Intestines / microbiology
  • Mice
  • Mice, Transgenic
  • Microbiota
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / physiopathology*
  • Peroxiredoxins / metabolism*
  • RNA, Ribosomal, 16S / genetics

Substances

  • RNA, Ribosomal, 16S
  • Peroxiredoxins

Grants and funding

This work was supported in part by Grants-in-Aid for Scientific Research (24790394) from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (to S.Y.) and by the Fukuoka Foundation for Sound Health Cancer Research Fund, Fukuoka, Japan (to S.Y.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.